Compare CGC & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CGC | AKBA |
|---|---|---|
| Founded | N/A | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.3M | 375.0M |
| IPO Year | 2023 | 2014 |
| Metric | CGC | AKBA |
|---|---|---|
| Price | $1.03 | $0.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $4.67 |
| AVG Volume (30 Days) | ★ 6.8M | 5.5M |
| Earning Date | 05-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 36.75 | ★ 93.94 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,759,000.00 | N/A |
| Revenue This Year | $8.27 | N/A |
| Revenue Next Year | $15.68 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.84 | $0.88 |
| 52 Week High | $2.38 | $4.08 |
| Indicator | CGC | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 44.05 | 34.17 |
| Support Level | $0.99 | $0.88 |
| Resistance Level | $1.23 | $1.56 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 40.22 | 23.90 |
Canopy Growth Corp, cultivates and sells medicinal and recreational cannabis and hemp through a portfolio of brands that include Doja, LivRelief, Ace Valley, Deep Space, and others. The Company is engaged in reportable segments namely: Canada cannabis, International markets cannabis, Storz & Bickel, and This Works. The company generates maximum revenue from Canadian cannabis.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.